Lilly Inks R&D Deal With Indian Firm Potentially Worth $100 Million
Indianapolis drug maker says that potential compounds could address therapeutic areas outside company's focus.
Indianapolis drug maker says that potential compounds could address therapeutic areas outside company's focus.